Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma

Grzegorz B. Gmyrek, Jeanette Pingel, Jaehyuk Choi*, Jonathan M. Green

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. All three mutant CD28 proteins examined enhanced CD28-dependent T cell proliferation and effector function. These data suggest that the mutant CD28 isoforms could accelerate tumor cell growth and increase tumor burden in affected patients. Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.

Original languageEnglish (US)
Pages (from-to)28-34
Number of pages7
JournalCellular Immunology
Volume319
DOIs
StatePublished - Sep 1 2017

Fingerprint

Cutaneous T-Cell Lymphoma
T-Lymphocytes
Mutation
Cell Proliferation
Neoplasms
T-Cell Lymphoma
Mutant Proteins
Tumor Burden
Protein Isoforms
Ligands
Survival
Growth
Therapeutics

Keywords

  • CD28
  • Costimulation
  • Cutaneous T cell lymphoma

ASJC Scopus subject areas

  • Immunology

Cite this

Gmyrek, Grzegorz B. ; Pingel, Jeanette ; Choi, Jaehyuk ; Green, Jonathan M. / Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. In: Cellular Immunology. 2017 ; Vol. 319. pp. 28-34.
@article{84522c23c591477ab28e3b1ecacb0479,
title = "Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma",
abstract = "CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. All three mutant CD28 proteins examined enhanced CD28-dependent T cell proliferation and effector function. These data suggest that the mutant CD28 isoforms could accelerate tumor cell growth and increase tumor burden in affected patients. Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.",
keywords = "CD28, Costimulation, Cutaneous T cell lymphoma",
author = "Gmyrek, {Grzegorz B.} and Jeanette Pingel and Jaehyuk Choi and Green, {Jonathan M.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.cellimm.2017.07.002",
language = "English (US)",
volume = "319",
pages = "28--34",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",

}

Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. / Gmyrek, Grzegorz B.; Pingel, Jeanette; Choi, Jaehyuk; Green, Jonathan M.

In: Cellular Immunology, Vol. 319, 01.09.2017, p. 28-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma

AU - Gmyrek, Grzegorz B.

AU - Pingel, Jeanette

AU - Choi, Jaehyuk

AU - Green, Jonathan M.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. All three mutant CD28 proteins examined enhanced CD28-dependent T cell proliferation and effector function. These data suggest that the mutant CD28 isoforms could accelerate tumor cell growth and increase tumor burden in affected patients. Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.

AB - CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. All three mutant CD28 proteins examined enhanced CD28-dependent T cell proliferation and effector function. These data suggest that the mutant CD28 isoforms could accelerate tumor cell growth and increase tumor burden in affected patients. Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.

KW - CD28

KW - Costimulation

KW - Cutaneous T cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85023206990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023206990&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2017.07.002

DO - 10.1016/j.cellimm.2017.07.002

M3 - Article

C2 - 28711152

AN - SCOPUS:85023206990

VL - 319

SP - 28

EP - 34

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

ER -